Clinical Candidates Targeting the ATR-CHK1-WEE1 Axis in Cancer
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378050%3A_____%2F21%3A00559749" target="_blank" >RIV/68378050:_____/21:00559749 - isvavai.cz</a>
Alternative codes found
RIV/00179906:_____/21:10425775
Result on the web
<a href="https://www.mdpi.com/2072-6694/13/4/795" target="_blank" >https://www.mdpi.com/2072-6694/13/4/795</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/cancers13040795" target="_blank" >10.3390/cancers13040795</a>
Alternative languages
Result language
angličtina
Original language name
Clinical Candidates Targeting the ATR-CHK1-WEE1 Axis in Cancer
Original language description
Selective killing of cancer cells while sparing healthy ones is the principle of the perfect cancer treatment and the primary aim of many oncologists, molecular biologists, and medicinal chemists. To achieve this goal, it is crucial to understand the molecular mechanisms that distinguish cancer cells from healthy ones. Accordingly, several clinical candidates that use particular mutations in cell-cycle progressions have been developed to kill cancer cells. As the majority of cancer cells have defects in G1 control, targeting the subsequent intra‑S or G2/M checkpoints has also been extensively pursued. This review focuses on clinical candidates that target the kinases involved in intra‑S and G2/M checkpoints, namely, ATR, CHK1, and WEE1 inhibitors. It provides insight into their current status and future perspectives for anticancer treatment. Overall, even though CHK1 inhibitors are still far from clinical establishment, promising accomplishments with ATR and WEE1 inhibitors in phase II trials present a positive outlook for patient survival.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Cancers (Basel)
ISSN
2072-6694
e-ISSN
2072-6694
Volume of the periodical
13
Issue of the periodical within the volume
4
Country of publishing house
CH - SWITZERLAND
Number of pages
22
Pages from-to
795
UT code for WoS article
000623387200001
EID of the result in the Scopus database
—